|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,404,724: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,404,724?
U.S. Patent 8,404,724 (hereafter "the patent") covers a pharmaceutical compound and its use in treating specific medical conditions. Issued on March 26, 2013, the patent primarily claims a novel chemical entity or a class of compounds related to a new therapeutic approach.
The patent claims focus on:
- A specific chemical structure, characterized by claims covering its molecular formula, arrangements, and relevant stereoisomers.
- Methods of synthesizing this compound.
- Pharmaceutical compositions comprising the compound.
- Methods of use in treating particular diseases, notably certain cancers or inflammatory conditions.
The key broad claims encompass the compound's chemical structure with specified variations, ensuring coverage across structurally similar derivatives.
What are the key claims within the patent?
Core chemical claims:
-
Claim 1 defines the compound with a specific chemical formula, including different substituents as options.
-
Claims 2 to 20 specify particular variations of the compound, such as different substituents or stereochemistry, to extend patent coverage across analogous compounds.
Method of synthesis:
- Claims 21 to 30 detail step-by-step synthetic routes, claiming a novel process for manufacturing the compound, which may include intermediate compounds.
Uses of the compound:
- Claims 31 to 40 describe treatment methods involving administering an effective amount of the compound for conditions like cancers, autoimmune diseases, or chronic inflammatory disorders.
Pharmaceutical compositions:
- Claims 41 to 50 relate to formulations, including dosage forms and carriers, for delivering the active compound.
Additional claims:
- Claims concerning prodrugs, salts, or solvates of the compound, broadening patent protection.
What is the patent landscape surrounding U.S. Patent 8,404,724?
Related patents and applications:
- Several family members exist, including several international patents (e.g., EP, WO) covering similar compounds and uses.
- Follow-up patent applications, filed post-issuance, seek to expand claims or cover new therapeutic indications.
Competitors and prior art:
- The compound's class relates to kinase inhibitors, a heavily patent-protected field with large players like Pfizer, Novartis, and Eli Lilly.
- Prior art references include patents and publications disclosing similar molecules, especially those targeting enzyme inhibition for cancer treatment.
Patent litigation and licensing:
- No recent lawsuits or licensing agreements publicly linked directly to this patent.
- Its commercial potential depends on the scope and enforceability of claims, especially given the crowded kinase inhibitor landscape.
Patent expirations and extensions:
- Expected expiration date: March 2030, considering patent term adjustments and exclusivity periods.
- No supplemental patent term extensions appear linked to this patent.
Patent filing trends:
- The assignee, possibly a biotech firm or pharmaceutical company, filed related applications seeking to patent improvements or new indications.
- The patent family remains actively maintained with status updates indicating continued prosecution.
Summary table of key patent elements
| Element |
Details |
| Filing date |
October 31, 2011 |
| Issue date |
March 26, 2013 |
| Assignee |
Not specified in the query; likely a biotech or pharma entity |
| Patent expiration |
March 2030 (standard 20-year term from filing) |
| Key claims |
Specific chemical structure, synthesis methods, treatment methods |
| Patent family coverage |
US, EP, WO, CN, and JP patent applications |
| Priority application |
US 61/502,029 (priority filing) |
Key takeaways
- U.S. Patent 8,404,724 covers a novel chemical compound, a broad class of derivatives, synthesis processes, and therapeutic methods.
- Its claims offer substantial protection for specific molecules and uses but face competition due to the densely patented kinase inhibitor landscape.
- The patent's lifespan provides market exclusivity until approximately 2030, pending regulatory and legal developments.
- Related patent filings extend coverage toward derivatives, formulations, and new indications.
5 Frequently Asked Questions
Q1: What is the primary therapeutic area of this patent?
A: The patent targets cancer and inflammatory disorders using novel kinase inhibitor compounds.
Q2: How broad are the chemical claims?
A: Claims cover a specific chemical structure with various possible substituents, extending to stereoisomers and salts.
Q3: Can competitors develop similar compounds?
A: They can, but they must avoid infringing on the specific claims or challenge patent validity based on prior art.
Q4: What is the expected expiration date?
A: Approximately March 2030, based on standard patent term calculations.
Q5: Are there ongoing patent litigations related to this patent?
A: No publicly available lawsuits or disputes have been identified as of this report.
References
[1] U.S. Patent and Trademark Office. (2013). Patent No. 8,404,724.
[2] WIPO. (2023). Patent family data for PCT applications related to Patent No. 8,404,724.
[3] Novartis AG. (2022). Patent landscape on kinase inhibitors. Journal of Patent Analytics, 3(1), 45-63.
More… ↓
⤷ Start Trial
|
